Calcified Tissue International

, Volume 88, Issue 3, pp 223–230 | Cite as

Does Anastrozole Affect Bone Resorption Similarly in Early and Late Postmenopausal Women?

  • Diane E. Powell
  • Richard A. Cochrane
  • Michael W. J. Davie
Original Research

Abstract

The aim of this study was to determine whether the bone-resorption response to anastrozole differed according to initial patient age in postmenopausal women with breast cancer in a cross-sectional study. Second-morning void urines were collected for measurement of urinary cross-linked N-telopeptide of type I collagen (uNTx, corrected for creatinine and log-transformed) from postmenopausal women, 99 with breast cancer on anastrozole (ABC), 88 with newly diagnosed breast cancer (NDBC), and 137 community-dwelling healthy control (HC) women. Bone mineral density (BMD) was also measured at the lumbar spine (LS, L2–L4) and the femoral neck (FN) in the ABC group. uNTx (nanomole bone collagen equivalents/millimole creatinine) levels increased with age in HC subjects. In patients <70 years, anastrozole treatment led to a significant increase in uNTx compared with age-related HC subjects (1.74 vs. 1.55, P < 0.005). Patients >70 years showed no such increase compared to HC (1.72 vs. 1.69, nonsignificant); however, NDBC women >70 years had uNTx levels significantly lower than HC women (1.59 vs. 1.69, P < 0.05). There was no difference in uNTx levels above and below the age of 70 years in NDBC women (1.56 vs. 1.59, nonsignificant). ABC women were more likely to have a positive LS BMD z score than age-matched controls. Anastrozole treatment increases bone turnover more in younger postmenopausal women with breast cancer than in older women compared to healthy controls. Higher LS BMD in ABC patients may help protect against fracture.

Keywords

Aromatase inhibitor Elderly Bone resorption Breast cancer Postmenopausal 

References

  1. 1.
    Baum M, Buzdar AU, Cuzick J, Forbes J, ATAC Trialist Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131–2139PubMedCrossRefGoogle Scholar
  2. 2.
    Thurlimann B, Keshaviah A, Coates AS, BIG 1-98 Collaborative Group (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747–2757PubMedCrossRefGoogle Scholar
  3. 3.
    Geisler J, King N, Dowsett M, Ottestad L, Lundgren S, Walton P, Kormeset PO, Lonning PE (1996) Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 74:1286–1291PubMedCrossRefGoogle Scholar
  4. 4.
    Dixon MJ, Renshaw L, Young O, Murray J, Macaskill EJ, McHugh M, Folkerd E, Cameron DA, A’Hern RP, Dowsett M (2008) Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol 26:1671–1676PubMedCrossRefGoogle Scholar
  5. 5.
    Baum M, Dowsett M, Cobion M, ATAC Trialists Group (2001) Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the “Arimidex and Tamoxifen Alone or in Combination” (ATAC) trial. Br J Cancer 85:317–324CrossRefGoogle Scholar
  6. 6.
    Rogers A, Saleh G, Hannon RA, Greenfield D, Eastell R (2002) Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 87:4470–4475PubMedCrossRefGoogle Scholar
  7. 7.
    Khosla S, Atkinson EJ, Melton LJ, Riggs BL (1997) Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a population-based study. J Clin Endocrinol Metab 82:1522–1527PubMedCrossRefGoogle Scholar
  8. 8.
    Chapurlat RD, Garnero P, Breart G, Meunier PJ, Delmas PD (2000) Serum estradiol and sex hormone-binding globulin and the risk of hip fracture in elderly women: the EPIDOS study. J Bone Miner Res 15:1835–1841PubMedCrossRefGoogle Scholar
  9. 9.
    Cummings SR, Browner WS, Bauer D, Stone K, Ensrud K, Jamal S, Ettinger B (1998) Endogenous hormones and the risk of hip and vertebral fractures among older women. N Engl J Med 339:733–738PubMedCrossRefGoogle Scholar
  10. 10.
    Heshmati HM, Khosla S, Robins SP, O’Fallon WM, Melton LJ, Riggs BL (2002) Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res 17:172–178PubMedCrossRefGoogle Scholar
  11. 11.
    McCloskey EV, Hannon RA, Lakner G, Fraser WD, Clack G, Miyamoto A, Finkelman RD, Eastell R (2007) Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur J Cancer 43:2523–2531PubMedCrossRefGoogle Scholar
  12. 12.
    Sone T, Miyake M, Takeda N, Fukunaga M (1995) Urinary excretion of type I collagen crosslinked N-telopeptides in healthy Japanese adults: age- and sex-related changes and reference limits. Bone 17:335–339PubMedCrossRefGoogle Scholar
  13. 13.
    Reginster JY, Henrotin Y, Christiansen C, Gamwell-Henriksen E, Bruyere O, Christgau S, Collette J (2001) Bone resorption in post-menopausal women with normal and low BMD assessed with biochemical markers specific for telopeptide derived degradation products of collagen type I. Calcif Tissue Int 69:130–137PubMedCrossRefGoogle Scholar
  14. 14.
    Hosie CJ, Hart DM, Smith DA, Al-Azzawi F (1989) Differential effect of long-term oestrogen therapy on trabecular and cortical bone. Maturitas 11:137–145PubMedCrossRefGoogle Scholar
  15. 15.
    Riggs BL, Melton LJ, Robb RA, Camp JJ, Atkinson EJ, McDaniel L, Amin S, Rouleau PA, Khosla S (2008) A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult men and women. J Bone Miner Res 23:205–214PubMedCrossRefGoogle Scholar
  16. 16.
    Berger C, Langsetmo L, Joseph L, Hanley DA, Davison KS, Josse R, Kreiger N, Tenenhouse A, Goltzman D (2008) Change in bone mineral density as a function of age in women and men and association with the use of antiresorptive agents. CMAJ 178:1660–1668PubMedGoogle Scholar
  17. 17.
    Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE (2006) Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 21:1215–1223PubMedCrossRefGoogle Scholar
  18. 18.
    Lester JE, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Hannon RA, Coleman RE (2008) Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 14:6336–6342PubMedCrossRefGoogle Scholar
  19. 19.
    McCaig FM, Renshaw L, Williams L, Young O, Murray J, Macaskill EJ, McHugh M, Hannon R, Dixon JM (2010) A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Res Treat 119:643–651PubMedCrossRefGoogle Scholar
  20. 20.
    Lonning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Offjord ES, Paolinin J, Polli A, Massimini G (2005) Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23:5126–5137PubMedCrossRefGoogle Scholar
  21. 21.
    Hadji P, Ziller M, Kieback DG, Menschik T, Kalder M, Kuck J, Hasenburg A (2009) The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial. Breast 18:159–164PubMedCrossRefGoogle Scholar
  22. 22.
    Confavreaux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD (2007) Estrogen-dependent increase in bone turnover and bone loss in postmenopausal with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 41:346–352CrossRefGoogle Scholar
  23. 23.
    van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, Barlow D, Makris A, Eastell R (2010) Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 28:967–975PubMedCrossRefGoogle Scholar
  24. 24.
    Quinn M, Babb P (2000) Cancer trends in England & Wales, 1950–1999. Health Stat Q 8:5–19Google Scholar
  25. 25.
    Anderson WF, Rosenberg PS, Menashe I, Mitani A, Pfeiffer RM (2008) Age-related cross-over in breast cancer incidence rates between black and white ethnic groups. J Natl Cancer Inst 100:1804–1814PubMedCrossRefGoogle Scholar
  26. 26.
    Murray BF, Smith D, Brady JJ, Healy ML, O’Higgins N, McDermot E, McKenna MJ, McKenna TJ (2006) Bone turnover markers in newly diagnosed breast cancer patients. Calcif Tissue Int 78(Suppl 1):S94–S95Google Scholar
  27. 27.
    Garnero P, Hausherr E, Chapuy M-C, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD (1996) Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res 11:1531–1538PubMedCrossRefGoogle Scholar
  28. 28.
    Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD (2000) Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 15:1526–1536PubMedCrossRefGoogle Scholar
  29. 29.
    Worsfold MW, Powell DE, Jones TWJ, Davie MWJ (2004) Assessment of urinary bone markers for monitoring osteoporosis treatment. Clin Chem 40:2263–2270CrossRefGoogle Scholar
  30. 30.
    Matthews JNS, Altman DG (1996) Interaction 3: how to examine heterogeneity. BMJ 313:862PubMedGoogle Scholar
  31. 31.
    Eastell R, Mallinak N, Weiss S, Ettinger M, Pettinger M, Cain D, Flessland K, Chesnut C (2000) Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women. J Bone Miner Res 15:594–598PubMedCrossRefGoogle Scholar
  32. 32.
    Fall PM, Kennedy D, Smith JA, Seibel MJ, Raisz LG (2000) Comparison of serum and urine assays for biochemical markers of bone resorption in postmenopausal women with and without hormone replacement therapy and in men. Osteoporos Int 11:481–485PubMedCrossRefGoogle Scholar
  33. 33.
    Krall EA, Dawson-Hughes B, Hirst K, Gallagher JC, Sherman SS, Dalsky G (1997) Bone mineral density and biochemical markers of bone turnover in healthy elderly men and women. J Gerontol 52A:M61–M67Google Scholar
  34. 34.
    Key T, Appleby P, Barnes I, Reeves G (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of 9 prospective studies. J Natl Cancer Inst 94:606–616PubMedGoogle Scholar
  35. 35.
    Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cumming SR (1999) Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Ann Intern Med 130:270–277PubMedGoogle Scholar
  36. 36.
    Sharp CA, Evans SF, Ristelli L, Worsfold M, Davie MWJ (1996) Effects of low- and conventional-dose transcutaneous HRT over 2 years on bone metabolism in younger and older postmenopausal women. Eur J Clin Invest 26:763–771PubMedCrossRefGoogle Scholar
  37. 37.
    Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, von Muhlen D (2000) Hysterectomy, oophrectomy and endogenous hormone levels in older women: the Rancho Bernardo study. J Clin Endocrinol Metab 85:645–651PubMedCrossRefGoogle Scholar
  38. 38.
    Bjornerem A, Straume B, Midtby M, Fonnebo V, Sundsfjord J, Svartberg J, Acharya G, Oian P, Bernsten GKR (2004) Endogenous sex hormones in relation to age, sex, lifestyle factors, and chronic diseases in a general population: the Tromso study. J Clin Endocrinol Metab 89:6039–6047PubMedCrossRefGoogle Scholar
  39. 39.
    Stone KL, Seeley DG, Lui LY, Cauley JA, Ensrud K, Browner WS, Nevitt MC, Cummings SR (2003) BMD at multiple sites and risk of fracture of multiple types: long-term results from the study of osteoporotic fractures. J Bone Miner Res 18:1947–1954PubMedCrossRefGoogle Scholar
  40. 40.
    Johnell O, Kanis JA, Oden A, Johnasson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton LJ, O’Neill T, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185–1194PubMedCrossRefGoogle Scholar
  41. 41.
    Douchi T, Yonehara Y, Kosha S, Iwamoto I, Rai Y, Sagara Y, Umekita Y (2007) Bone mineral density in breast cancer patients with positive estrogen receptor tumor status. Maturitas 57:221–225PubMedCrossRefGoogle Scholar
  42. 42.
    Ganry O, Tramier B, Fardellone P, Raverdy N, Dubreuil A (2001) High bone-mass density as a marker for breast cancer in post-menopausal women. Breast 10:313–317PubMedCrossRefGoogle Scholar
  43. 43.
    Nguyen TV, Center JR, Eisman JA (2000) Association between breast cancer and bone mineral density: the Dubbo Osteoporosis Epidemiology Study. Maturitas 36:27–34PubMedCrossRefGoogle Scholar
  44. 44.
    Stewart A, Kumar V, Torgerson DJ, Fraser WD, Gilbert FJ, Reid DM (2005) Axial BMD, changes in BMD and bone turnover do not predict breast cancer incidence in early postmenopausal women. Osteoporos Int 16:1627–1632PubMedCrossRefGoogle Scholar
  45. 45.
    Tremollieres FA, Pouilles J-M, Laparra J, Ribot C (2008) Bone mineral density at menopause does not predict breast cancer incidence. Osteoporos Int 19:1497–1504PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Diane E. Powell
    • 1
  • Richard A. Cochrane
    • 2
  • Michael W. J. Davie
    • 1
  1. 1.Charles Salt Centre for Human MetabolismRobert Jones & Agnes Hunt Orthopaedic & District Hospital NHS TrustShropshireUK
  2. 2.Breast Unit, Wrexham Maelor HospitalWrexhamUK

Personalised recommendations